- Home
- NCL vs APRE Comparison
NCL vs APRE Comparison
Compare NCL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- APRE
- Stock Information
- Founded
- NCL 2013
- APRE 2006
- Country
- NCL United States
- APRE United States
- Employees
- NCL N/A
- APRE N/A
- Industry
- NCL
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCL
- APRE Health Care
- Exchange
- NCL Nasdaq
- APRE Nasdaq
- Market Cap
- NCL 12.2M
- APRE 13.5M
- IPO Year
- NCL 2023
- APRE 2019
- Fundamental
- Price
- NCL $0.20
- APRE $1.70
- Analyst Decision
- NCL
- APRE Strong Buy
- Analyst Count
- NCL 0
- APRE 2
- Target Price
- NCL N/A
- APRE $15.50
- AVG Volume (30 Days)
- NCL 145.4K
- APRE 27.0K
- Earning Date
- NCL 05-19-2025
- APRE 05-13-2025
- Dividend Yield
- NCL N/A
- APRE N/A
- EPS Growth
- NCL N/A
- APRE N/A
- EPS
- NCL N/A
- APRE N/A
- Revenue
- NCL $15,576,857.00
- APRE $1,502,581.00
- Revenue This Year
- NCL N/A
- APRE N/A
- Revenue Next Year
- NCL N/A
- APRE N/A
- P/E Ratio
- NCL N/A
- APRE N/A
- Revenue Growth
- NCL 47.13
- APRE 157.63
- 52 Week Low
- NCL $0.15
- APRE $1.67
- 52 Week High
- NCL $0.69
- APRE $6.40
- Technical
- Relative Strength Index (RSI)
- NCL 42.49
- APRE 23.11
- Support Level
- NCL $0.19
- APRE $2.17
- Resistance Level
- NCL $0.22
- APRE $2.30
- Average True Range (ATR)
- NCL 0.02
- APRE 0.16
- MACD
- NCL 0.00
- APRE -0.02
- Stochastic Oscillator
- NCL 18.75
- APRE 3.06
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.